Statera Biopharma Inc.

Statera Biopharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies aimed at restoring immune balance and homeostasis. Its core focus is on creating novel treatments for conditions where the immune system plays a critical role, such as autoimmune disorders, neutropenia, anemia, emerging viral infections, and various cancers. Utilizing its proprietary Advanced Immunomodulating Multi-Component System (AIMS) platform, Statera Biopharma integrates diverse pharmacological factors including potency, selectivity, and pharmacokinetic-pharmacodynamic relationships to engineer its therapies. The company’s portfolio features late-stage candidates, with products in development for indications like Crohn's disease, hematological conditions, and inflammatory diseases. Additionally, Statera’s pipeline incorporates toll-like receptor (TLR) agonists and antagonists designed to modulate immune responses. Through these efforts, Statera Biopharma seeks to establish a new paradigm in immunotherapy by addressing complex diseases with comprehensive and safety-focused drug profiles, positioning itself within the biotechnology and pharmaceutical research sectors as an innovator in immune system modulation.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Michael Kevin Handley

Employees

46

Headquarters

Fort Collins, CO, United States

Website

www.staterabiopharma.com